Application of ticagrelor combined with aspirin antiplatelet therapy in high-risk non-disabling ischemic cerebrovascular events

WANG Lichuang; SU Ruiya; JIANG Kang

doi:10.6039/j.issn.1001-0408.2026.11.14

您当前的位置：

首页 >

文章列表页 >

Application of ticagrelor combined with aspirin antiplatelet therapy in high-risk non-disabling ischemic cerebrovascular events

更新时间：2026-06-10

- Application of ticagrelor combined with aspirin antiplatelet therapy in high-risk non-disabling ischemic cerebrovascular events
- ZHONGGUO YAOFANG Vol. 37, Issue 11, Pages: 1462-1467(2026)
- 作者机构：
  
  1.南阳医学高等专科学校临床系，河南南阳　473061
  2.南阳医学高等专科学校第一附属医院冠心病监护病房，河南南阳　473000
  3.南阳医学高等专科学校第一附属医院神经内科，河南南阳　473000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2026.11.14
  CLC： R969.4;R743
- Received：21 January 2026，
  
  Revised：2026-05-26，
  
  Accepted：27 May 2026，
  
  Published：15 June 2026
- 稿件说明：
移动端阅览
王力闯,苏蕊雅,江康.替格瑞洛联合阿司匹林抗血小板方案在高危非致残性缺血性脑血管事件中的应用 [J].中国药房,2026,37(11):1462-1467.

WANG Lichuang,SU Ruiya,JIANG Kang.Application of ticagrelor combined with aspirin antiplatelet therapy in high-risk non-disabling ischemic cerebrovascular events[J].ZHONGGUO YAOFANG,2026,37(11):1462-1467.
王力闯,苏蕊雅,江康.替格瑞洛联合阿司匹林抗血小板方案在高危非致残性缺血性脑血管事件中的应用 [J].中国药房,2026,37(11):1462-1467. DOI： 10.6039/j.issn.1001-0408.2026.11.14.

WANG Lichuang,SU Ruiya,JIANG Kang.Application of ticagrelor combined with aspirin antiplatelet therapy in high-risk non-disabling ischemic cerebrovascular events[J].ZHONGGUO YAOFANG,2026,37(11):1462-1467. DOI： 10.6039/j.issn.1001-0408.2026.11.14.

摘要

目的

探索替格瑞洛联合阿司匹林抗血小板方案在高危非致残性缺血性脑血管事件（HR-NICE）中的应用效果。

方法

回顾性选择2023年1月1日至2025年1月1日于南阳医学高等专科学校第一附属医院就诊的232例HR-NICE患者为研究对象，根据不同的抗血小板治疗方案将其分为3组：A组（78例）采用氯吡格雷首日300 mg负荷后再以75 mg，qd联合阿司匹林100 mg，qd；B组（69例）采用替格瑞洛首日120 mg负荷后再以60 mg，bid联合阿司匹林100 mg，qd；C组（85例）采用替格瑞洛首日180 mg负荷后再以90 mg，bid联合阿司匹林100 mg，qd；各组双联抗血小板治疗21 d后改为阿司匹林单药维持。比较3组患者的主要观察结局[早期神经功能恶化（END）发生率]和次要观察结局（出院后90 d内缺血性事件发生率、30/90 d预后良好的比例、90 d内出血事件发生率）。采用Logistic回归模型分析不同抗血小板治疗方案与END发生风险之间的关系，并进一步纳入治疗方案与人口学及临床基线特征的交互项，分析不同亚组患者中治疗方案与END发生风险之间的交互效应。采用倾向评分匹配（PSM）进行稳健性分析验证。

结果

在主要观察结局上，C组患者的END发生率明显低于A组（

＜0.05）；在次要观察结局上，3组患者出院后90 d内缺血性事件发生率、30/90 d预后良好的比例比较，差异均无统计学意义（

＞0.05）；B组和C组患者轻度出血事件的发生率明显高于A组（

＜0.05）；3组患者在中度和严重出血事件的发生率上差异无统计学意义（

＞0.05）。交互效应分析结果显示，缺血性脑血管病、年龄-血压-临床症状-症状持续时间-糖尿病评分（ABCD2）、REACH风险评分及埃森卒中评分（ESSEN）与治疗方案之间存在显著交互作用（

＜0.05）；在合并缺血性脑血管病以及ABCD2≥6分、REACH风险评分≥6分、ESSEN≥3分的患者中，B组或C组方案相较于A组方案与更低的END发生风险相关。PSM分析结果与匹配前分析方向基本一致。

结论

替格瑞洛（尤其是90 mg，bid）联合阿司匹林方案与HR-NICE患者较低的END发生风险相关，但会增加轻度出血事件发生风险。合并缺血性脑血管病及具有较高ABCD2、REACH风险评分、ESSEN的患者可能为该联合方案的潜在获益人群。

Abstract

OBJECTIVE

To explore the application effect of ticagrelor combined with aspirin antiplatelet therapy in high-risk non-disabling ischemic cerebrovascular events （HR-NICE）.

METHODS

A total of 232 patients with HR-NICE treated at the First Affiliated Hospital of Nanyang Medical College from January 1， 2023 to January 1， 2025 were retrospectively selected. According to different antiplatelet regimens， the patients were divided into three groups： group A （78 cases） received clopidogrel 300 mg as a loading dose on the first day， followed by clopidogrel 75 mg， qd combined with aspirin 100 mg， qd； group B （69 cases） received ticagrelor 120 mg as a loading dose on the first day， followed by ticagrelor 60 mg， bid combined with aspirin 100 mg， qd； group C （85 cases） received ticagrelor 180 mg as a loading dose on the first day， followed by ticagrelor 90 mg， bid combined with aspirin 100 mg， qd. All groups received dual-antiplatelet therapy for 21 days and were then switched to aspirin monotherapy. The primary outcome [incidence of early neurological deterioration （END）] and secondary outcomes， including incidence of ischemic events within 90 days post-discharge， favorable prognosis at 30/90 days， and incidence of bleeding events within 90 days， were compared among the three groups. Logistic regression was used to analyze the relationship between different antiplatelet regimens and END. Interaction terms between treatment regimen and demographic and clinical baseline characteristics were further included to evaluate the interaction effect between treatment regimen and END risk in different subgroups. Propensity score matching （PSM） was performed for sensitivity analysis.

RESULTS

For the primary outcome， the incidence of END in group C was significantly lower than that in group A （

＜0.05）. For secondary outcomes， there were no statistically significant differences among the three groups in the incidence of ischemic events within 90 days post-discharge， favorable prognosis at 30/90 days （

＞0.05）. The incidence of minor bleeding events in groups B and C was significantly higher than that in group A （

＜0.05）， while no significant differences were observed among the three groups in moderate or severe bleeding events （

＞0.05）. Interaction analysis showed that ischemic cerebrovascular disease， Age-Blood Pressure-Clinical Feature-Duration-Diabetes Score （ABCD2）， REACH risk score， and Essen Stroke Risk Score （ESSEN） had significant interactions with treatment regimen （

＜0.05）. Among patients with ischemic cerebrovascular disease， ABCD2≥6 points， REACH risk score≥6 points， or ESSEN≥3 points， regimens B or C were associated with a lower risk of END compared with regimen A. The PSM results were generally consistent with the analysis before matching.

CONCLUSIONS

Ticagrelor， especially the 90 mg bid regimen， plus aspirin， was associated with a lower risk of END in patients with HR-NICE， but increased the risk of minor bleeding events. Patients with ischemic cerebrovascular disease and higher ABCD2， REACH risk score， or ESSEN may be potential beneficiaries of this combination regimen.

关键词

Keywords

references

LIU Z Z ， WU S D ， LIN X M ， et al . Impact of age on clinical characteristics and 1-year outcomes of non-disabling ischemic cerebrovascular events：a multicenter prospective cohort study [J ] . BMC Geriatr ， 2024 ， 24 （ 1 ）： 884 .

LIU S M ， GAO Z E ， MENG R ， et al . Preventing ischemic cerebrovascular events in high-risk patients with non-disabling ischemic cerebrovascular events using remote ischemic conditioning：a single-arm study [J ] . Front Neurol ， 2021 ， 12 ： 748916 .

中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组 . 轻型卒中临床诊疗中国专家共识： 2024版 [J ] . 中华神经科杂志， 2025 ， 58 （ 5 ）： 462 - 474 .

POWERS W J ， RABINSTEIN A A ， ACKERSON T ， et al . Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association [J ] . Stroke ， 2019 ， 50 （ 12 ）： e344 - e418 .

DAWSON J ， MERWICK Á ， WEBB A ， et al . European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA [J ] . Eur Stroke J ， 2021 ， 6 （ 2 ）： Ⅵ .

PAN Y S ， MENG X ， JIN A M ， et al . Time course for benefit and risk with ticagrelor and aspirin in individuals with acute ischemic stroke or transient ischemic attack who carry CYP2C19 loss-of-function alleles：a secondary analysis of the CHANCE-2 randomized clinical trial [J ] . JAMA Neurol ， 2022 ， 79 （ 8 ）： 739 - 745 .

DE GODOY TORSO N ， RODRIGUES-SOARES F ， ALTAMIRANO C ， et al . CYP2C19 genotype-phenotype correlation：current insights and unanswered questions [J ] . Drug Metab Pers Ther ， 2025 ， 39 （ 4 ）： 201 - 206 .

KWAN J ， HAND P . Early neurological deterioration in acute stroke：clinical characteristics and impact on outcome [J ] . QJM ， 2006 ， 99 （ 9 ）： 625 - 633 .

SAVER J L ， CHAISINANUNKUL N ， CAMPBELL B C V ， et al . Standardized nomenclature for modified Rankin scale global disability outcomes：consensus recommendations from stroke therapy academic industry roundtable Ⅺ [J ] . Stroke ， 2021 ， 52 （ 9 ）： 3054 - 3062 .

GUSTO investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction [J ] . N Engl J Med ， 1993 ， 329 （ 10 ）： 673 - 682 .

CHEN Z Z ， LI M C ， WU Z H ， et al . Cerebral circulation time is a potential predictor of disabling ischemic cerebrovascular events in patients with non-disabling middle cerebral artery stenosis [J ] . Front Neurol ， 2021 ， 12 ： 653752 .

WANG A X ， MENG X ， TIAN X ， et al . Bleeding risk of dual antiplatelet therapy after minor stroke or transient ischemic attack [J ] . Ann Neurol ， 2022 ， 91 （ 3 ）： 380 - 388 .

ZHANG X M ， JING J ， WANG A X ， et al . Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention：a subgroup analysis of the CHANCE-2 trial [J ] . Stroke Vasc Neurol ， 2024 ， 9 （ 5 ）： 541 - 550 .

JIANG M E ， LI G M ， HE Q M ， et al . Multimodal imaging evaluation of early neurological deterioration following acute ischemic stroke [J ] . Quant Imaging Med Surg ， 2024 ， 14 （ 7 ）： 4763 - 4778 .

GE Z ， KAN J ， GAO X F ， et al . Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes （ULTIMATE-DAPT）：a randomised，placebo-controlled，double-blind clinical trial [J ] . Lancet ， 2024 ， 403 （ 10439 ）： 1866 - 1878 .

LUN R ， DHALIWAL S ， ZITIKYTE G ， et al . Comparison of ticagrelor vs clopidogrel in addition to aspirin in patients with minor ischemic stroke and transient ischemic attack：a network meta-analysis [J ] . JAMA Neurol ， 2022 ， 79 （ 2 ）： 141 - 148 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

阿司匹林联合跌打化瘀散预防大隐静脉曲张术后深静脉栓形成的临床观察

替格瑞洛对比普拉格雷对血小板反应性影响的Meta分析

急性冠状动脉综合征患者初始应用氯吡格雷后换用替格瑞洛的疗效与安全性评价

阿司匹林-β-环糊精包合物PLGA微球的制备及其质量控制

氯吡格雷联合阿司匹林治疗老年短暂性脑缺血发作的临床观察

Related Author

WANG Jun-li

LUO Zhen-chun

WU Yumeng

CHENG Lichun

LIANG Jing

LIU Lilong

SUN Xiangju

SONG Jia

Related Institution

No data

⁰